Research News
BrightFocus Foundation’s Alzheimer’s Fast Track, an immersive workshop for early-career scientists, was held Nov. 8-10 in Washington, D.C. and convened 80 talented Alzheimer’s researchers from 19 U.S. states and six countries, including Japan, Spain, and Sweden.
To achieve true health equity, we must ensure that all populations have equitable access to clinical trials and the benefits of medical research. With the right mix of resources, dedication, compassion, patience, and time, we can positively impact communities nationwide, write BrightFocus President and CEO Stacy Pagos Haller and board member Tonya M. Matthews, PhD, in a new op-ed.
An updated drug shows promise in treating traumatic brain injuries that can lead to neurodegenerative diseases.
A team of researchers including Alzheimer’s Disease Research grantee Eunhee Kim, PhD, have used a 3D brain cell culture model to show that the exercise-induced muscle hormone, irisin, reduces the level of amyloid beta associated with Alzheimer’s disease.
A new study bridging neuroscience and machine learning offers insights into the potential role of astrocytes in the human brain.
A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
A BrightFocus-funded research team has some eye-opening news: They’ve used artificial intelligence to develop a model that could one day detect Alzheimer’s disease through photographs of the eye, which could lead to earlier diagnosis and treatment.
